Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remdesivir + tocilizumab
- Development stage
- Phase 3
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (remdesivir), Intravenous (tocilizumab)
01
Overview
remdesivir + tocilizumab is a **combination therapy** involving the antiviral small molecule remdesivir and the monoclonal antibody tocilizumab, used experimentally for the management of severe COVID-19. **Remdesivir** is a nucleoside analog that inhibits the RNA-dependent RNA polymerase of SARS-CoV-2, blocking viral replication. **Tocilizumab** is a humanized monoclonal antibody that targets the interleukin-6 receptor (IL-6R), inhibiting IL-6-mediated inflammatory signaling implicated in cytokine storm and acute respiratory distress syndrome. Combined use is intended to address both viral replication (remdesivir) and hyperinflammatory response (tocilizumab) in COVID-19. Clinical studies indicate the combination results in improved clinical outcomes (reduced mortality, faster clinical improvement, shorter ICU and hospital stay, improved lung recovery) compared to corticosteroid therapy, but does not demonstrate a statistically significant survival advantage[1][2].
- Other names
- remdesivir + tocilizumab
02
Targets
IL-6R (Interleukin-6 receptor subunit alpha)Mpro (3C-like proteinase of SARS-CoV-2)M protein (SARS-CoV-2 membrane protein)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on remdesivir + tocilizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remdesivir + tocilizumab.